Commercial biopharma with improving cash generation, net cash, and internally funded pipeline optionality, balanced against LUPKYNIS concentration and patent risk.

Infrastructure coatings compounder with niche market leadership, high Metal Coatings margins, and disciplined capital allocation, balanced against valuation and cyclical demand.

Cash-generative mixed-signal franchise with a customer-concentration discount and diversification optionality beyond Apple.

Underfollowed growth + value candidate with renewed current acceleration, marketplace scaling, and a valuation discount tied to governance and geopolitical diligence.

Profitable growth, commercial diversification, and pipeline optionality anchored by INGREZZA, CRENESSITY, VYKAT XR, and late-stage psychiatry programs.

Structural AI infrastructure thesis around memory bandwidth, semiconductor products, silicon IP, royalties, and valuation-duration risk.